Jun. 11 at 12:40 PM
$CTXR Two other significant items in the body of this morning's prospectus.
1) They confirm they filed an appeal for the delisting notice. No date given for the hearing yet.
"The Company timely requested an appeal of the Listing Qualification’s Department determination, which stayed the suspension and delisting of the Company’s common stock pending the Nasdaq Hearings Panel’s decision."
2) They stated that
$CTOR is expected to launch Lymphir in the 2nd Half of 2025: